OXALIEVA 50 mg contains Oxaliplatin, a third-generation platinum-based chemotherapy (anticancer) drug. It works by forming DNA cross-links, which inhibit DNA synthesis and transcription, leading to cancer cell death. Oxaliplatin is especially effective in colorectal cancer and has less kidney and hearing toxicity than cisplatin.

Oxaliplatin Injection is used in the treatment of:

•  Colorectal cancer (adjuvant and metastatic)

•  Gastric (stomach) cancer

•  Pancreatic cancer

•  Ovarian cancer (off-label, in combinations)

  Commonly used in FOLFOX regimen (with 5-FU and leucovorin).

Common side effects:

•  Peripheral neuropathy (tingling, numbness)

•  Cold-induced sensitivity (throat tightness, hand pain)

•  Nausea and vomiting

•  Diarrhea

•  Fatigue

•  Myelosuppression

Serious side effects:

        • Severe peripheral neuropathy

        • Hypersensitivity reactions

        • Severe diarrhea

        • Liver enzyme abnormalities

Avoid exposure to cold during and after infusion to reduce neuropathy.

Dosage depends on body surface area (BSA) and treatment regimen.

Common dosing:

       •  85 mg/m² IV infusion every 2 weeks

       •  130 mg/m² IV infusion every 3 weeks

 Administered as slow intravenous infusion under oncologist supervision.